Global Hemoperfusion

Hemoperfusion Comprehensive Study by Type (Charcoal Hemoperfusion, Certain Resins Hemoperfusion), Application (Drug Intoxication, Hepatic Encephalopathy, Others), Hemoperfusion Devices (DiaKart, Biocompatible System, Hemokart or Alukart, Adsorba, Hemopur, Others), Raw Material (Polypropylene, Polycarbonate, Membrane Materials, Activated Carbon), Sorbent (Petroleum Based Charcoal, Norit, Norit Extruded Charcoal, Others) Players and Region - Global Market Outlook to 2030

Hemoperfusion Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 13%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Hemoperfusion
Hemoperfusion is a treatment that is used to handle large volumes of the patient’s blood and is passed over an adsorbent substance from the blood. Adsorption is a process through which molecules and particles are attracted to the surface of the solid material held there. It is a treatment of chronic uremia which is focusing on reducing the generation of the nitrogenous end products.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)
CAGR13.0%


The global hemoperfusion market is moderately competitive and it is having of some leading players. In terms of vendors share, some of the leading players are highly dominating the global market. These leading market players are focusing on strategic growth initiatives which enhanced their market share to improve their business profitability. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Hemoperfusion market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Gambro (United States), Organon-Teknika (United States), Smith and Nephew (United Kingdom), Cytosorbents (United States), Asahi-Kasei (Japan), Biosun Medical (China), Toray Medical (Japan), Jafron Biomedical (China), Baxter International (United States) and Kaneka Corporation (Japan) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Toray Medical Co. Ltd. (Japan), Fresenius SE & Co. KGaA (Germany), B. Braun Melsungen AG (Germany) and Abbott Laboratories (United States).

Segmentation Overview
AMA Research has segmented the market of Global Hemoperfusion market by Type (Charcoal Hemoperfusion and Certain Resins Hemoperfusion), Application (Drug Intoxication, Hepatic Encephalopathy and Others) and Region.



On the basis of geography, the market of Hemoperfusion has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Hemoperfusion Devices, the sub-segment i.e. DiaKart will boost the Hemoperfusion market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Raw Material, the sub-segment i.e. Polypropylene will boost the Hemoperfusion market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Sorbent, the sub-segment i.e. Petroleum Based Charcoal will boost the Hemoperfusion market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Increased Use of Hemoperfusion in Healthcare Such As Providing Supportive Treatment Before and After Transplantation for Patients In Case Of Liver Failure and Others

Market Growth Drivers:
Increasing Utilization of Adsorbent Substance Technique to Remove Toxic Substances and Poisons, Rising Investment from the Emerging Countries Such As China, India and Rapid Growth in End User Industries Is Booming the Market in Hemoperfusion

Challenges:
Lack of Consumer Awareness

Restraints:
Rising Concern towards Risks Such As Infection, Blood Clotting, Destruction of Blood Platelets, And Organ Failure

Opportunities:
Rising Investment of Research and Development Innovative and Increasing Prevalence of Blood Disorders Such As Platelet Disorder and Bleeding Problem

Market Leaders and their expansionary development strategies
In June 2022, CytoSorbents Corporation announced that following a successful pilot program in three countries, the Company has signed an expanded non-exclusive agreement with Nikkiso Europe GmbH (Nikkiso) to distribute their PureADJUST stand-alone hemoperfusion pump and accessories
In Feb 2020, Baxter International Inc. announced the agreement to deal with Spectral Medical Inc. for the blood filter in the United States and Canada region. Basically, it is a hemoperfusion filter and endotoxin activity assay, a diagnostic tool. It is an investigating device in the United States.


Key Target Audience
Venture Capitalists and Private Equity Firms, New Entrants/Investors, Analysts and Strategic Business Planners, Hemoperfusion Devices Manufacturers, Suppliers and Distributors, Raw Material Suppliers, Government Regulatory and Research Organizations and End-Use Industries

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Charcoal Hemoperfusion
  • Certain Resins Hemoperfusion
By Application
  • Drug Intoxication
  • Hepatic Encephalopathy
  • Others
By Hemoperfusion Devices
  • DiaKart
  • Biocompatible System
  • Hemokart or Alukart
  • Adsorba
  • Hemopur
  • Others

By Raw Material
  • Polypropylene
  • Polycarbonate
  • Membrane Materials
  • Activated Carbon

By Sorbent
  • Petroleum Based Charcoal
  • Norit
  • Norit Extruded Charcoal
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Utilization of Adsorbent Substance Technique to Remove Toxic Substances and Poisons
      • 3.2.2. Rising Investment from the Emerging Countries Such As China, India
      • 3.2.3. Rapid Growth in End User Industries Is Booming the Market in Hemoperfusion
    • 3.3. Market Challenges
      • 3.3.1. Lack of Consumer Awareness
    • 3.4. Market Trends
      • 3.4.1. Increased Use of Hemoperfusion in Healthcare Such As Providing Supportive Treatment Before and After Transplantation for Patients In Case Of Liver Failure and Others
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Hemoperfusion, by Type, Application, Hemoperfusion Devices, Raw Material, Sorbent and Region (value, volume and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Hemoperfusion (Value)
      • 5.2.1. Global Hemoperfusion by: Type (Value)
        • 5.2.1.1. Charcoal Hemoperfusion
        • 5.2.1.2. Certain Resins Hemoperfusion
      • 5.2.2. Global Hemoperfusion by: Application (Value)
        • 5.2.2.1. Drug Intoxication
        • 5.2.2.2. Hepatic Encephalopathy
        • 5.2.2.3. Others
      • 5.2.3. Global Hemoperfusion by: Hemoperfusion Devices (Value)
        • 5.2.3.1. DiaKart
        • 5.2.3.2. Biocompatible System
        • 5.2.3.3. Hemokart or Alukart
        • 5.2.3.4. Adsorba
        • 5.2.3.5. Hemopur
        • 5.2.3.6. Others
      • 5.2.4. Global Hemoperfusion by: Raw Material (Value)
        • 5.2.4.1. Polypropylene
        • 5.2.4.2. Polycarbonate
        • 5.2.4.3. Membrane Materials
        • 5.2.4.4. Activated Carbon
      • 5.2.5. Global Hemoperfusion by: Sorbent (Value)
        • 5.2.5.1. Petroleum Based Charcoal
        • 5.2.5.2. Norit
        • 5.2.5.3. Norit Extruded Charcoal
        • 5.2.5.4. Others
      • 5.2.6. Global Hemoperfusion Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
    • 5.3. Global Hemoperfusion (Volume)
      • 5.3.1. Global Hemoperfusion by: Type (Volume)
        • 5.3.1.1. Charcoal Hemoperfusion
        • 5.3.1.2. Certain Resins Hemoperfusion
      • 5.3.2. Global Hemoperfusion by: Application (Volume)
        • 5.3.2.1. Drug Intoxication
        • 5.3.2.2. Hepatic Encephalopathy
        • 5.3.2.3. Others
      • 5.3.3. Global Hemoperfusion by: Hemoperfusion Devices (Volume)
        • 5.3.3.1. DiaKart
        • 5.3.3.2. Biocompatible System
        • 5.3.3.3. Hemokart or Alukart
        • 5.3.3.4. Adsorba
        • 5.3.3.5. Hemopur
        • 5.3.3.6. Others
      • 5.3.4. Global Hemoperfusion by: Raw Material (Volume)
        • 5.3.4.1. Polypropylene
        • 5.3.4.2. Polycarbonate
        • 5.3.4.3. Membrane Materials
        • 5.3.4.4. Activated Carbon
      • 5.3.5. Global Hemoperfusion by: Sorbent (Volume)
        • 5.3.5.1. Petroleum Based Charcoal
        • 5.3.5.2. Norit
        • 5.3.5.3. Norit Extruded Charcoal
        • 5.3.5.4. Others
      • 5.3.6. Global Hemoperfusion Region
        • 5.3.6.1. South America
          • 5.3.6.1.1. Brazil
          • 5.3.6.1.2. Argentina
          • 5.3.6.1.3. Rest of South America
        • 5.3.6.2. Asia Pacific
          • 5.3.6.2.1. China
          • 5.3.6.2.2. Japan
          • 5.3.6.2.3. India
          • 5.3.6.2.4. South Korea
          • 5.3.6.2.5. Taiwan
          • 5.3.6.2.6. Australia
          • 5.3.6.2.7. Rest of Asia-Pacific
        • 5.3.6.3. Europe
          • 5.3.6.3.1. Germany
          • 5.3.6.3.2. France
          • 5.3.6.3.3. Italy
          • 5.3.6.3.4. United Kingdom
          • 5.3.6.3.5. Netherlands
          • 5.3.6.3.6. Rest of Europe
        • 5.3.6.4. MEA
          • 5.3.6.4.1. Middle East
          • 5.3.6.4.2. Africa
        • 5.3.6.5. North America
          • 5.3.6.5.1. United States
          • 5.3.6.5.2. Canada
          • 5.3.6.5.3. Mexico
    • 5.4. Global Hemoperfusion (Price)
      • 5.4.1. Global Hemoperfusion by: Type (Price)
  • 6. Hemoperfusion: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Gambro (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Organon-Teknika (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Smith and Nephew (United Kingdom)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Cytosorbents (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Asahi-Kasei (Japan)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Biosun Medical (China)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Toray Medical (Japan)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Jafron Biomedical (China)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Baxter International (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Kaneka Corporation (Japan)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Hemoperfusion Sale, by Type, Application, Hemoperfusion Devices, Raw Material, Sorbent and Region (value, volume and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Hemoperfusion (Value)
      • 7.2.1. Global Hemoperfusion by: Type (Value)
        • 7.2.1.1. Charcoal Hemoperfusion
        • 7.2.1.2. Certain Resins Hemoperfusion
      • 7.2.2. Global Hemoperfusion by: Application (Value)
        • 7.2.2.1. Drug Intoxication
        • 7.2.2.2. Hepatic Encephalopathy
        • 7.2.2.3. Others
      • 7.2.3. Global Hemoperfusion by: Hemoperfusion Devices (Value)
        • 7.2.3.1. DiaKart
        • 7.2.3.2. Biocompatible System
        • 7.2.3.3. Hemokart or Alukart
        • 7.2.3.4. Adsorba
        • 7.2.3.5. Hemopur
        • 7.2.3.6. Others
      • 7.2.4. Global Hemoperfusion by: Raw Material (Value)
        • 7.2.4.1. Polypropylene
        • 7.2.4.2. Polycarbonate
        • 7.2.4.3. Membrane Materials
        • 7.2.4.4. Activated Carbon
      • 7.2.5. Global Hemoperfusion by: Sorbent (Value)
        • 7.2.5.1. Petroleum Based Charcoal
        • 7.2.5.2. Norit
        • 7.2.5.3. Norit Extruded Charcoal
        • 7.2.5.4. Others
      • 7.2.6. Global Hemoperfusion Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
    • 7.3. Global Hemoperfusion (Volume)
      • 7.3.1. Global Hemoperfusion by: Type (Volume)
        • 7.3.1.1. Charcoal Hemoperfusion
        • 7.3.1.2. Certain Resins Hemoperfusion
      • 7.3.2. Global Hemoperfusion by: Application (Volume)
        • 7.3.2.1. Drug Intoxication
        • 7.3.2.2. Hepatic Encephalopathy
        • 7.3.2.3. Others
      • 7.3.3. Global Hemoperfusion by: Hemoperfusion Devices (Volume)
        • 7.3.3.1. DiaKart
        • 7.3.3.2. Biocompatible System
        • 7.3.3.3. Hemokart or Alukart
        • 7.3.3.4. Adsorba
        • 7.3.3.5. Hemopur
        • 7.3.3.6. Others
      • 7.3.4. Global Hemoperfusion by: Raw Material (Volume)
        • 7.3.4.1. Polypropylene
        • 7.3.4.2. Polycarbonate
        • 7.3.4.3. Membrane Materials
        • 7.3.4.4. Activated Carbon
      • 7.3.5. Global Hemoperfusion by: Sorbent (Volume)
        • 7.3.5.1. Petroleum Based Charcoal
        • 7.3.5.2. Norit
        • 7.3.5.3. Norit Extruded Charcoal
        • 7.3.5.4. Others
      • 7.3.6. Global Hemoperfusion Region
        • 7.3.6.1. South America
          • 7.3.6.1.1. Brazil
          • 7.3.6.1.2. Argentina
          • 7.3.6.1.3. Rest of South America
        • 7.3.6.2. Asia Pacific
          • 7.3.6.2.1. China
          • 7.3.6.2.2. Japan
          • 7.3.6.2.3. India
          • 7.3.6.2.4. South Korea
          • 7.3.6.2.5. Taiwan
          • 7.3.6.2.6. Australia
          • 7.3.6.2.7. Rest of Asia-Pacific
        • 7.3.6.3. Europe
          • 7.3.6.3.1. Germany
          • 7.3.6.3.2. France
          • 7.3.6.3.3. Italy
          • 7.3.6.3.4. United Kingdom
          • 7.3.6.3.5. Netherlands
          • 7.3.6.3.6. Rest of Europe
        • 7.3.6.4. MEA
          • 7.3.6.4.1. Middle East
          • 7.3.6.4.2. Africa
        • 7.3.6.5. North America
          • 7.3.6.5.1. United States
          • 7.3.6.5.2. Canada
          • 7.3.6.5.3. Mexico
    • 7.4. Global Hemoperfusion (Price)
      • 7.4.1. Global Hemoperfusion by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Hemoperfusion: by Type(USD Million)
  • Table 2. Hemoperfusion Charcoal Hemoperfusion , by Region USD Million (2018-2023)
  • Table 3. Hemoperfusion Certain Resins Hemoperfusion , by Region USD Million (2018-2023)
  • Table 4. Hemoperfusion: by Application(USD Million)
  • Table 5. Hemoperfusion Drug Intoxication , by Region USD Million (2018-2023)
  • Table 6. Hemoperfusion Hepatic Encephalopathy , by Region USD Million (2018-2023)
  • Table 7. Hemoperfusion Others , by Region USD Million (2018-2023)
  • Table 8. Hemoperfusion: by Hemoperfusion Devices(USD Million)
  • Table 9. Hemoperfusion DiaKart , by Region USD Million (2018-2023)
  • Table 10. Hemoperfusion Biocompatible System , by Region USD Million (2018-2023)
  • Table 11. Hemoperfusion Hemokart or Alukart , by Region USD Million (2018-2023)
  • Table 12. Hemoperfusion Adsorba , by Region USD Million (2018-2023)
  • Table 13. Hemoperfusion Hemopur , by Region USD Million (2018-2023)
  • Table 14. Hemoperfusion Others , by Region USD Million (2018-2023)
  • Table 15. Hemoperfusion: by Raw Material(USD Million)
  • Table 16. Hemoperfusion Polypropylene , by Region USD Million (2018-2023)
  • Table 17. Hemoperfusion Polycarbonate , by Region USD Million (2018-2023)
  • Table 18. Hemoperfusion Membrane Materials , by Region USD Million (2018-2023)
  • Table 19. Hemoperfusion Activated Carbon , by Region USD Million (2018-2023)
  • Table 20. Hemoperfusion: by Sorbent(USD Million)
  • Table 21. Hemoperfusion Petroleum Based Charcoal , by Region USD Million (2018-2023)
  • Table 22. Hemoperfusion Norit , by Region USD Million (2018-2023)
  • Table 23. Hemoperfusion Norit Extruded Charcoal , by Region USD Million (2018-2023)
  • Table 24. Hemoperfusion Others , by Region USD Million (2018-2023)
  • Table 25. South America Hemoperfusion, by Country USD Million (2018-2023)
  • Table 26. South America Hemoperfusion, by Type USD Million (2018-2023)
  • Table 27. South America Hemoperfusion, by Application USD Million (2018-2023)
  • Table 28. South America Hemoperfusion, by Hemoperfusion Devices USD Million (2018-2023)
  • Table 29. South America Hemoperfusion, by Raw Material USD Million (2018-2023)
  • Table 30. South America Hemoperfusion, by Sorbent USD Million (2018-2023)
  • Table 31. Brazil Hemoperfusion, by Type USD Million (2018-2023)
  • Table 32. Brazil Hemoperfusion, by Application USD Million (2018-2023)
  • Table 33. Brazil Hemoperfusion, by Hemoperfusion Devices USD Million (2018-2023)
  • Table 34. Brazil Hemoperfusion, by Raw Material USD Million (2018-2023)
  • Table 35. Brazil Hemoperfusion, by Sorbent USD Million (2018-2023)
  • Table 36. Argentina Hemoperfusion, by Type USD Million (2018-2023)
  • Table 37. Argentina Hemoperfusion, by Application USD Million (2018-2023)
  • Table 38. Argentina Hemoperfusion, by Hemoperfusion Devices USD Million (2018-2023)
  • Table 39. Argentina Hemoperfusion, by Raw Material USD Million (2018-2023)
  • Table 40. Argentina Hemoperfusion, by Sorbent USD Million (2018-2023)
  • Table 41. Rest of South America Hemoperfusion, by Type USD Million (2018-2023)
  • Table 42. Rest of South America Hemoperfusion, by Application USD Million (2018-2023)
  • Table 43. Rest of South America Hemoperfusion, by Hemoperfusion Devices USD Million (2018-2023)
  • Table 44. Rest of South America Hemoperfusion, by Raw Material USD Million (2018-2023)
  • Table 45. Rest of South America Hemoperfusion, by Sorbent USD Million (2018-2023)
  • Table 46. Asia Pacific Hemoperfusion, by Country USD Million (2018-2023)
  • Table 47. Asia Pacific Hemoperfusion, by Type USD Million (2018-2023)
  • Table 48. Asia Pacific Hemoperfusion, by Application USD Million (2018-2023)
  • Table 49. Asia Pacific Hemoperfusion, by Hemoperfusion Devices USD Million (2018-2023)
  • Table 50. Asia Pacific Hemoperfusion, by Raw Material USD Million (2018-2023)
  • Table 51. Asia Pacific Hemoperfusion, by Sorbent USD Million (2018-2023)
  • Table 52. China Hemoperfusion, by Type USD Million (2018-2023)
  • Table 53. China Hemoperfusion, by Application USD Million (2018-2023)
  • Table 54. China Hemoperfusion, by Hemoperfusion Devices USD Million (2018-2023)
  • Table 55. China Hemoperfusion, by Raw Material USD Million (2018-2023)
  • Table 56. China Hemoperfusion, by Sorbent USD Million (2018-2023)
  • Table 57. Japan Hemoperfusion, by Type USD Million (2018-2023)
  • Table 58. Japan Hemoperfusion, by Application USD Million (2018-2023)
  • Table 59. Japan Hemoperfusion, by Hemoperfusion Devices USD Million (2018-2023)
  • Table 60. Japan Hemoperfusion, by Raw Material USD Million (2018-2023)
  • Table 61. Japan Hemoperfusion, by Sorbent USD Million (2018-2023)
  • Table 62. India Hemoperfusion, by Type USD Million (2018-2023)
  • Table 63. India Hemoperfusion, by Application USD Million (2018-2023)
  • Table 64. India Hemoperfusion, by Hemoperfusion Devices USD Million (2018-2023)
  • Table 65. India Hemoperfusion, by Raw Material USD Million (2018-2023)
  • Table 66. India Hemoperfusion, by Sorbent USD Million (2018-2023)
  • Table 67. South Korea Hemoperfusion, by Type USD Million (2018-2023)
  • Table 68. South Korea Hemoperfusion, by Application USD Million (2018-2023)
  • Table 69. South Korea Hemoperfusion, by Hemoperfusion Devices USD Million (2018-2023)
  • Table 70. South Korea Hemoperfusion, by Raw Material USD Million (2018-2023)
  • Table 71. South Korea Hemoperfusion, by Sorbent USD Million (2018-2023)
  • Table 72. Taiwan Hemoperfusion, by Type USD Million (2018-2023)
  • Table 73. Taiwan Hemoperfusion, by Application USD Million (2018-2023)
  • Table 74. Taiwan Hemoperfusion, by Hemoperfusion Devices USD Million (2018-2023)
  • Table 75. Taiwan Hemoperfusion, by Raw Material USD Million (2018-2023)
  • Table 76. Taiwan Hemoperfusion, by Sorbent USD Million (2018-2023)
  • Table 77. Australia Hemoperfusion, by Type USD Million (2018-2023)
  • Table 78. Australia Hemoperfusion, by Application USD Million (2018-2023)
  • Table 79. Australia Hemoperfusion, by Hemoperfusion Devices USD Million (2018-2023)
  • Table 80. Australia Hemoperfusion, by Raw Material USD Million (2018-2023)
  • Table 81. Australia Hemoperfusion, by Sorbent USD Million (2018-2023)
  • Table 82. Rest of Asia-Pacific Hemoperfusion, by Type USD Million (2018-2023)
  • Table 83. Rest of Asia-Pacific Hemoperfusion, by Application USD Million (2018-2023)
  • Table 84. Rest of Asia-Pacific Hemoperfusion, by Hemoperfusion Devices USD Million (2018-2023)
  • Table 85. Rest of Asia-Pacific Hemoperfusion, by Raw Material USD Million (2018-2023)
  • Table 86. Rest of Asia-Pacific Hemoperfusion, by Sorbent USD Million (2018-2023)
  • Table 87. Europe Hemoperfusion, by Country USD Million (2018-2023)
  • Table 88. Europe Hemoperfusion, by Type USD Million (2018-2023)
  • Table 89. Europe Hemoperfusion, by Application USD Million (2018-2023)
  • Table 90. Europe Hemoperfusion, by Hemoperfusion Devices USD Million (2018-2023)
  • Table 91. Europe Hemoperfusion, by Raw Material USD Million (2018-2023)
  • Table 92. Europe Hemoperfusion, by Sorbent USD Million (2018-2023)
  • Table 93. Germany Hemoperfusion, by Type USD Million (2018-2023)
  • Table 94. Germany Hemoperfusion, by Application USD Million (2018-2023)
  • Table 95. Germany Hemoperfusion, by Hemoperfusion Devices USD Million (2018-2023)
  • Table 96. Germany Hemoperfusion, by Raw Material USD Million (2018-2023)
  • Table 97. Germany Hemoperfusion, by Sorbent USD Million (2018-2023)
  • Table 98. France Hemoperfusion, by Type USD Million (2018-2023)
  • Table 99. France Hemoperfusion, by Application USD Million (2018-2023)
  • Table 100. France Hemoperfusion, by Hemoperfusion Devices USD Million (2018-2023)
  • Table 101. France Hemoperfusion, by Raw Material USD Million (2018-2023)
  • Table 102. France Hemoperfusion, by Sorbent USD Million (2018-2023)
  • Table 103. Italy Hemoperfusion, by Type USD Million (2018-2023)
  • Table 104. Italy Hemoperfusion, by Application USD Million (2018-2023)
  • Table 105. Italy Hemoperfusion, by Hemoperfusion Devices USD Million (2018-2023)
  • Table 106. Italy Hemoperfusion, by Raw Material USD Million (2018-2023)
  • Table 107. Italy Hemoperfusion, by Sorbent USD Million (2018-2023)
  • Table 108. United Kingdom Hemoperfusion, by Type USD Million (2018-2023)
  • Table 109. United Kingdom Hemoperfusion, by Application USD Million (2018-2023)
  • Table 110. United Kingdom Hemoperfusion, by Hemoperfusion Devices USD Million (2018-2023)
  • Table 111. United Kingdom Hemoperfusion, by Raw Material USD Million (2018-2023)
  • Table 112. United Kingdom Hemoperfusion, by Sorbent USD Million (2018-2023)
  • Table 113. Netherlands Hemoperfusion, by Type USD Million (2018-2023)
  • Table 114. Netherlands Hemoperfusion, by Application USD Million (2018-2023)
  • Table 115. Netherlands Hemoperfusion, by Hemoperfusion Devices USD Million (2018-2023)
  • Table 116. Netherlands Hemoperfusion, by Raw Material USD Million (2018-2023)
  • Table 117. Netherlands Hemoperfusion, by Sorbent USD Million (2018-2023)
  • Table 118. Rest of Europe Hemoperfusion, by Type USD Million (2018-2023)
  • Table 119. Rest of Europe Hemoperfusion, by Application USD Million (2018-2023)
  • Table 120. Rest of Europe Hemoperfusion, by Hemoperfusion Devices USD Million (2018-2023)
  • Table 121. Rest of Europe Hemoperfusion, by Raw Material USD Million (2018-2023)
  • Table 122. Rest of Europe Hemoperfusion, by Sorbent USD Million (2018-2023)
  • Table 123. MEA Hemoperfusion, by Country USD Million (2018-2023)
  • Table 124. MEA Hemoperfusion, by Type USD Million (2018-2023)
  • Table 125. MEA Hemoperfusion, by Application USD Million (2018-2023)
  • Table 126. MEA Hemoperfusion, by Hemoperfusion Devices USD Million (2018-2023)
  • Table 127. MEA Hemoperfusion, by Raw Material USD Million (2018-2023)
  • Table 128. MEA Hemoperfusion, by Sorbent USD Million (2018-2023)
  • Table 129. Middle East Hemoperfusion, by Type USD Million (2018-2023)
  • Table 130. Middle East Hemoperfusion, by Application USD Million (2018-2023)
  • Table 131. Middle East Hemoperfusion, by Hemoperfusion Devices USD Million (2018-2023)
  • Table 132. Middle East Hemoperfusion, by Raw Material USD Million (2018-2023)
  • Table 133. Middle East Hemoperfusion, by Sorbent USD Million (2018-2023)
  • Table 134. Africa Hemoperfusion, by Type USD Million (2018-2023)
  • Table 135. Africa Hemoperfusion, by Application USD Million (2018-2023)
  • Table 136. Africa Hemoperfusion, by Hemoperfusion Devices USD Million (2018-2023)
  • Table 137. Africa Hemoperfusion, by Raw Material USD Million (2018-2023)
  • Table 138. Africa Hemoperfusion, by Sorbent USD Million (2018-2023)
  • Table 139. North America Hemoperfusion, by Country USD Million (2018-2023)
  • Table 140. North America Hemoperfusion, by Type USD Million (2018-2023)
  • Table 141. North America Hemoperfusion, by Application USD Million (2018-2023)
  • Table 142. North America Hemoperfusion, by Hemoperfusion Devices USD Million (2018-2023)
  • Table 143. North America Hemoperfusion, by Raw Material USD Million (2018-2023)
  • Table 144. North America Hemoperfusion, by Sorbent USD Million (2018-2023)
  • Table 145. United States Hemoperfusion, by Type USD Million (2018-2023)
  • Table 146. United States Hemoperfusion, by Application USD Million (2018-2023)
  • Table 147. United States Hemoperfusion, by Hemoperfusion Devices USD Million (2018-2023)
  • Table 148. United States Hemoperfusion, by Raw Material USD Million (2018-2023)
  • Table 149. United States Hemoperfusion, by Sorbent USD Million (2018-2023)
  • Table 150. Canada Hemoperfusion, by Type USD Million (2018-2023)
  • Table 151. Canada Hemoperfusion, by Application USD Million (2018-2023)
  • Table 152. Canada Hemoperfusion, by Hemoperfusion Devices USD Million (2018-2023)
  • Table 153. Canada Hemoperfusion, by Raw Material USD Million (2018-2023)
  • Table 154. Canada Hemoperfusion, by Sorbent USD Million (2018-2023)
  • Table 155. Mexico Hemoperfusion, by Type USD Million (2018-2023)
  • Table 156. Mexico Hemoperfusion, by Application USD Million (2018-2023)
  • Table 157. Mexico Hemoperfusion, by Hemoperfusion Devices USD Million (2018-2023)
  • Table 158. Mexico Hemoperfusion, by Raw Material USD Million (2018-2023)
  • Table 159. Mexico Hemoperfusion, by Sorbent USD Million (2018-2023)
  • Table 160. Hemoperfusion Sales: by Type(K Units)
  • Table 161. Hemoperfusion Sales Charcoal Hemoperfusion , by Region K Units (2018-2023)
  • Table 162. Hemoperfusion Sales Certain Resins Hemoperfusion , by Region K Units (2018-2023)
  • Table 163. Hemoperfusion Sales: by Application(K Units)
  • Table 164. Hemoperfusion Sales Drug Intoxication , by Region K Units (2018-2023)
  • Table 165. Hemoperfusion Sales Hepatic Encephalopathy , by Region K Units (2018-2023)
  • Table 166. Hemoperfusion Sales Others , by Region K Units (2018-2023)
  • Table 167. Hemoperfusion Sales: by Hemoperfusion Devices(K Units)
  • Table 168. Hemoperfusion Sales DiaKart , by Region K Units (2018-2023)
  • Table 169. Hemoperfusion Sales Biocompatible System , by Region K Units (2018-2023)
  • Table 170. Hemoperfusion Sales Hemokart or Alukart , by Region K Units (2018-2023)
  • Table 171. Hemoperfusion Sales Adsorba , by Region K Units (2018-2023)
  • Table 172. Hemoperfusion Sales Hemopur , by Region K Units (2018-2023)
  • Table 173. Hemoperfusion Sales Others , by Region K Units (2018-2023)
  • Table 174. Hemoperfusion Sales: by Raw Material(K Units)
  • Table 175. Hemoperfusion Sales Polypropylene , by Region K Units (2018-2023)
  • Table 176. Hemoperfusion Sales Polycarbonate , by Region K Units (2018-2023)
  • Table 177. Hemoperfusion Sales Membrane Materials , by Region K Units (2018-2023)
  • Table 178. Hemoperfusion Sales Activated Carbon , by Region K Units (2018-2023)
  • Table 179. Hemoperfusion Sales: by Sorbent(K Units)
  • Table 180. Hemoperfusion Sales Petroleum Based Charcoal , by Region K Units (2018-2023)
  • Table 181. Hemoperfusion Sales Norit , by Region K Units (2018-2023)
  • Table 182. Hemoperfusion Sales Norit Extruded Charcoal , by Region K Units (2018-2023)
  • Table 183. Hemoperfusion Sales Others , by Region K Units (2018-2023)
  • Table 184. South America Hemoperfusion Sales, by Country K Units (2018-2023)
  • Table 185. South America Hemoperfusion Sales, by Type K Units (2018-2023)
  • Table 186. South America Hemoperfusion Sales, by Application K Units (2018-2023)
  • Table 187. South America Hemoperfusion Sales, by Hemoperfusion Devices K Units (2018-2023)
  • Table 188. South America Hemoperfusion Sales, by Raw Material K Units (2018-2023)
  • Table 189. South America Hemoperfusion Sales, by Sorbent K Units (2018-2023)
  • Table 190. Brazil Hemoperfusion Sales, by Type K Units (2018-2023)
  • Table 191. Brazil Hemoperfusion Sales, by Application K Units (2018-2023)
  • Table 192. Brazil Hemoperfusion Sales, by Hemoperfusion Devices K Units (2018-2023)
  • Table 193. Brazil Hemoperfusion Sales, by Raw Material K Units (2018-2023)
  • Table 194. Brazil Hemoperfusion Sales, by Sorbent K Units (2018-2023)
  • Table 195. Argentina Hemoperfusion Sales, by Type K Units (2018-2023)
  • Table 196. Argentina Hemoperfusion Sales, by Application K Units (2018-2023)
  • Table 197. Argentina Hemoperfusion Sales, by Hemoperfusion Devices K Units (2018-2023)
  • Table 198. Argentina Hemoperfusion Sales, by Raw Material K Units (2018-2023)
  • Table 199. Argentina Hemoperfusion Sales, by Sorbent K Units (2018-2023)
  • Table 200. Rest of South America Hemoperfusion Sales, by Type K Units (2018-2023)
  • Table 201. Rest of South America Hemoperfusion Sales, by Application K Units (2018-2023)
  • Table 202. Rest of South America Hemoperfusion Sales, by Hemoperfusion Devices K Units (2018-2023)
  • Table 203. Rest of South America Hemoperfusion Sales, by Raw Material K Units (2018-2023)
  • Table 204. Rest of South America Hemoperfusion Sales, by Sorbent K Units (2018-2023)
  • Table 205. Asia Pacific Hemoperfusion Sales, by Country K Units (2018-2023)
  • Table 206. Asia Pacific Hemoperfusion Sales, by Type K Units (2018-2023)
  • Table 207. Asia Pacific Hemoperfusion Sales, by Application K Units (2018-2023)
  • Table 208. Asia Pacific Hemoperfusion Sales, by Hemoperfusion Devices K Units (2018-2023)
  • Table 209. Asia Pacific Hemoperfusion Sales, by Raw Material K Units (2018-2023)
  • Table 210. Asia Pacific Hemoperfusion Sales, by Sorbent K Units (2018-2023)
  • Table 211. China Hemoperfusion Sales, by Type K Units (2018-2023)
  • Table 212. China Hemoperfusion Sales, by Application K Units (2018-2023)
  • Table 213. China Hemoperfusion Sales, by Hemoperfusion Devices K Units (2018-2023)
  • Table 214. China Hemoperfusion Sales, by Raw Material K Units (2018-2023)
  • Table 215. China Hemoperfusion Sales, by Sorbent K Units (2018-2023)
  • Table 216. Japan Hemoperfusion Sales, by Type K Units (2018-2023)
  • Table 217. Japan Hemoperfusion Sales, by Application K Units (2018-2023)
  • Table 218. Japan Hemoperfusion Sales, by Hemoperfusion Devices K Units (2018-2023)
  • Table 219. Japan Hemoperfusion Sales, by Raw Material K Units (2018-2023)
  • Table 220. Japan Hemoperfusion Sales, by Sorbent K Units (2018-2023)
  • Table 221. India Hemoperfusion Sales, by Type K Units (2018-2023)
  • Table 222. India Hemoperfusion Sales, by Application K Units (2018-2023)
  • Table 223. India Hemoperfusion Sales, by Hemoperfusion Devices K Units (2018-2023)
  • Table 224. India Hemoperfusion Sales, by Raw Material K Units (2018-2023)
  • Table 225. India Hemoperfusion Sales, by Sorbent K Units (2018-2023)
  • Table 226. South Korea Hemoperfusion Sales, by Type K Units (2018-2023)
  • Table 227. South Korea Hemoperfusion Sales, by Application K Units (2018-2023)
  • Table 228. South Korea Hemoperfusion Sales, by Hemoperfusion Devices K Units (2018-2023)
  • Table 229. South Korea Hemoperfusion Sales, by Raw Material K Units (2018-2023)
  • Table 230. South Korea Hemoperfusion Sales, by Sorbent K Units (2018-2023)
  • Table 231. Taiwan Hemoperfusion Sales, by Type K Units (2018-2023)
  • Table 232. Taiwan Hemoperfusion Sales, by Application K Units (2018-2023)
  • Table 233. Taiwan Hemoperfusion Sales, by Hemoperfusion Devices K Units (2018-2023)
  • Table 234. Taiwan Hemoperfusion Sales, by Raw Material K Units (2018-2023)
  • Table 235. Taiwan Hemoperfusion Sales, by Sorbent K Units (2018-2023)
  • Table 236. Australia Hemoperfusion Sales, by Type K Units (2018-2023)
  • Table 237. Australia Hemoperfusion Sales, by Application K Units (2018-2023)
  • Table 238. Australia Hemoperfusion Sales, by Hemoperfusion Devices K Units (2018-2023)
  • Table 239. Australia Hemoperfusion Sales, by Raw Material K Units (2018-2023)
  • Table 240. Australia Hemoperfusion Sales, by Sorbent K Units (2018-2023)
  • Table 241. Rest of Asia-Pacific Hemoperfusion Sales, by Type K Units (2018-2023)
  • Table 242. Rest of Asia-Pacific Hemoperfusion Sales, by Application K Units (2018-2023)
  • Table 243. Rest of Asia-Pacific Hemoperfusion Sales, by Hemoperfusion Devices K Units (2018-2023)
  • Table 244. Rest of Asia-Pacific Hemoperfusion Sales, by Raw Material K Units (2018-2023)
  • Table 245. Rest of Asia-Pacific Hemoperfusion Sales, by Sorbent K Units (2018-2023)
  • Table 246. Europe Hemoperfusion Sales, by Country K Units (2018-2023)
  • Table 247. Europe Hemoperfusion Sales, by Type K Units (2018-2023)
  • Table 248. Europe Hemoperfusion Sales, by Application K Units (2018-2023)
  • Table 249. Europe Hemoperfusion Sales, by Hemoperfusion Devices K Units (2018-2023)
  • Table 250. Europe Hemoperfusion Sales, by Raw Material K Units (2018-2023)
  • Table 251. Europe Hemoperfusion Sales, by Sorbent K Units (2018-2023)
  • Table 252. Germany Hemoperfusion Sales, by Type K Units (2018-2023)
  • Table 253. Germany Hemoperfusion Sales, by Application K Units (2018-2023)
  • Table 254. Germany Hemoperfusion Sales, by Hemoperfusion Devices K Units (2018-2023)
  • Table 255. Germany Hemoperfusion Sales, by Raw Material K Units (2018-2023)
  • Table 256. Germany Hemoperfusion Sales, by Sorbent K Units (2018-2023)
  • Table 257. France Hemoperfusion Sales, by Type K Units (2018-2023)
  • Table 258. France Hemoperfusion Sales, by Application K Units (2018-2023)
  • Table 259. France Hemoperfusion Sales, by Hemoperfusion Devices K Units (2018-2023)
  • Table 260. France Hemoperfusion Sales, by Raw Material K Units (2018-2023)
  • Table 261. France Hemoperfusion Sales, by Sorbent K Units (2018-2023)
  • Table 262. Italy Hemoperfusion Sales, by Type K Units (2018-2023)
  • Table 263. Italy Hemoperfusion Sales, by Application K Units (2018-2023)
  • Table 264. Italy Hemoperfusion Sales, by Hemoperfusion Devices K Units (2018-2023)
  • Table 265. Italy Hemoperfusion Sales, by Raw Material K Units (2018-2023)
  • Table 266. Italy Hemoperfusion Sales, by Sorbent K Units (2018-2023)
  • Table 267. United Kingdom Hemoperfusion Sales, by Type K Units (2018-2023)
  • Table 268. United Kingdom Hemoperfusion Sales, by Application K Units (2018-2023)
  • Table 269. United Kingdom Hemoperfusion Sales, by Hemoperfusion Devices K Units (2018-2023)
  • Table 270. United Kingdom Hemoperfusion Sales, by Raw Material K Units (2018-2023)
  • Table 271. United Kingdom Hemoperfusion Sales, by Sorbent K Units (2018-2023)
  • Table 272. Netherlands Hemoperfusion Sales, by Type K Units (2018-2023)
  • Table 273. Netherlands Hemoperfusion Sales, by Application K Units (2018-2023)
  • Table 274. Netherlands Hemoperfusion Sales, by Hemoperfusion Devices K Units (2018-2023)
  • Table 275. Netherlands Hemoperfusion Sales, by Raw Material K Units (2018-2023)
  • Table 276. Netherlands Hemoperfusion Sales, by Sorbent K Units (2018-2023)
  • Table 277. Rest of Europe Hemoperfusion Sales, by Type K Units (2018-2023)
  • Table 278. Rest of Europe Hemoperfusion Sales, by Application K Units (2018-2023)
  • Table 279. Rest of Europe Hemoperfusion Sales, by Hemoperfusion Devices K Units (2018-2023)
  • Table 280. Rest of Europe Hemoperfusion Sales, by Raw Material K Units (2018-2023)
  • Table 281. Rest of Europe Hemoperfusion Sales, by Sorbent K Units (2018-2023)
  • Table 282. MEA Hemoperfusion Sales, by Country K Units (2018-2023)
  • Table 283. MEA Hemoperfusion Sales, by Type K Units (2018-2023)
  • Table 284. MEA Hemoperfusion Sales, by Application K Units (2018-2023)
  • Table 285. MEA Hemoperfusion Sales, by Hemoperfusion Devices K Units (2018-2023)
  • Table 286. MEA Hemoperfusion Sales, by Raw Material K Units (2018-2023)
  • Table 287. MEA Hemoperfusion Sales, by Sorbent K Units (2018-2023)
  • Table 288. Middle East Hemoperfusion Sales, by Type K Units (2018-2023)
  • Table 289. Middle East Hemoperfusion Sales, by Application K Units (2018-2023)
  • Table 290. Middle East Hemoperfusion Sales, by Hemoperfusion Devices K Units (2018-2023)
  • Table 291. Middle East Hemoperfusion Sales, by Raw Material K Units (2018-2023)
  • Table 292. Middle East Hemoperfusion Sales, by Sorbent K Units (2018-2023)
  • Table 293. Africa Hemoperfusion Sales, by Type K Units (2018-2023)
  • Table 294. Africa Hemoperfusion Sales, by Application K Units (2018-2023)
  • Table 295. Africa Hemoperfusion Sales, by Hemoperfusion Devices K Units (2018-2023)
  • Table 296. Africa Hemoperfusion Sales, by Raw Material K Units (2018-2023)
  • Table 297. Africa Hemoperfusion Sales, by Sorbent K Units (2018-2023)
  • Table 298. North America Hemoperfusion Sales, by Country K Units (2018-2023)
  • Table 299. North America Hemoperfusion Sales, by Type K Units (2018-2023)
  • Table 300. North America Hemoperfusion Sales, by Application K Units (2018-2023)
  • Table 301. North America Hemoperfusion Sales, by Hemoperfusion Devices K Units (2018-2023)
  • Table 302. North America Hemoperfusion Sales, by Raw Material K Units (2018-2023)
  • Table 303. North America Hemoperfusion Sales, by Sorbent K Units (2018-2023)
  • Table 304. United States Hemoperfusion Sales, by Type K Units (2018-2023)
  • Table 305. United States Hemoperfusion Sales, by Application K Units (2018-2023)
  • Table 306. United States Hemoperfusion Sales, by Hemoperfusion Devices K Units (2018-2023)
  • Table 307. United States Hemoperfusion Sales, by Raw Material K Units (2018-2023)
  • Table 308. United States Hemoperfusion Sales, by Sorbent K Units (2018-2023)
  • Table 309. Canada Hemoperfusion Sales, by Type K Units (2018-2023)
  • Table 310. Canada Hemoperfusion Sales, by Application K Units (2018-2023)
  • Table 311. Canada Hemoperfusion Sales, by Hemoperfusion Devices K Units (2018-2023)
  • Table 312. Canada Hemoperfusion Sales, by Raw Material K Units (2018-2023)
  • Table 313. Canada Hemoperfusion Sales, by Sorbent K Units (2018-2023)
  • Table 314. Mexico Hemoperfusion Sales, by Type K Units (2018-2023)
  • Table 315. Mexico Hemoperfusion Sales, by Application K Units (2018-2023)
  • Table 316. Mexico Hemoperfusion Sales, by Hemoperfusion Devices K Units (2018-2023)
  • Table 317. Mexico Hemoperfusion Sales, by Raw Material K Units (2018-2023)
  • Table 318. Mexico Hemoperfusion Sales, by Sorbent K Units (2018-2023)
  • Table 319. Hemoperfusion: by Type(USD/Units)
  • Table 320. Company Basic Information, Sales Area and Its Competitors
  • Table 321. Company Basic Information, Sales Area and Its Competitors
  • Table 322. Company Basic Information, Sales Area and Its Competitors
  • Table 323. Company Basic Information, Sales Area and Its Competitors
  • Table 324. Company Basic Information, Sales Area and Its Competitors
  • Table 325. Company Basic Information, Sales Area and Its Competitors
  • Table 326. Company Basic Information, Sales Area and Its Competitors
  • Table 327. Company Basic Information, Sales Area and Its Competitors
  • Table 328. Company Basic Information, Sales Area and Its Competitors
  • Table 329. Company Basic Information, Sales Area and Its Competitors
  • Table 330. Hemoperfusion: by Type(USD Million)
  • Table 331. Hemoperfusion Charcoal Hemoperfusion , by Region USD Million (2025-2030)
  • Table 332. Hemoperfusion Certain Resins Hemoperfusion , by Region USD Million (2025-2030)
  • Table 333. Hemoperfusion: by Application(USD Million)
  • Table 334. Hemoperfusion Drug Intoxication , by Region USD Million (2025-2030)
  • Table 335. Hemoperfusion Hepatic Encephalopathy , by Region USD Million (2025-2030)
  • Table 336. Hemoperfusion Others , by Region USD Million (2025-2030)
  • Table 337. Hemoperfusion: by Hemoperfusion Devices(USD Million)
  • Table 338. Hemoperfusion DiaKart , by Region USD Million (2025-2030)
  • Table 339. Hemoperfusion Biocompatible System , by Region USD Million (2025-2030)
  • Table 340. Hemoperfusion Hemokart or Alukart , by Region USD Million (2025-2030)
  • Table 341. Hemoperfusion Adsorba , by Region USD Million (2025-2030)
  • Table 342. Hemoperfusion Hemopur , by Region USD Million (2025-2030)
  • Table 343. Hemoperfusion Others , by Region USD Million (2025-2030)
  • Table 344. Hemoperfusion: by Raw Material(USD Million)
  • Table 345. Hemoperfusion Polypropylene , by Region USD Million (2025-2030)
  • Table 346. Hemoperfusion Polycarbonate , by Region USD Million (2025-2030)
  • Table 347. Hemoperfusion Membrane Materials , by Region USD Million (2025-2030)
  • Table 348. Hemoperfusion Activated Carbon , by Region USD Million (2025-2030)
  • Table 349. Hemoperfusion: by Sorbent(USD Million)
  • Table 350. Hemoperfusion Petroleum Based Charcoal , by Region USD Million (2025-2030)
  • Table 351. Hemoperfusion Norit , by Region USD Million (2025-2030)
  • Table 352. Hemoperfusion Norit Extruded Charcoal , by Region USD Million (2025-2030)
  • Table 353. Hemoperfusion Others , by Region USD Million (2025-2030)
  • Table 354. South America Hemoperfusion, by Country USD Million (2025-2030)
  • Table 355. South America Hemoperfusion, by Type USD Million (2025-2030)
  • Table 356. South America Hemoperfusion, by Application USD Million (2025-2030)
  • Table 357. South America Hemoperfusion, by Hemoperfusion Devices USD Million (2025-2030)
  • Table 358. South America Hemoperfusion, by Raw Material USD Million (2025-2030)
  • Table 359. South America Hemoperfusion, by Sorbent USD Million (2025-2030)
  • Table 360. Brazil Hemoperfusion, by Type USD Million (2025-2030)
  • Table 361. Brazil Hemoperfusion, by Application USD Million (2025-2030)
  • Table 362. Brazil Hemoperfusion, by Hemoperfusion Devices USD Million (2025-2030)
  • Table 363. Brazil Hemoperfusion, by Raw Material USD Million (2025-2030)
  • Table 364. Brazil Hemoperfusion, by Sorbent USD Million (2025-2030)
  • Table 365. Argentina Hemoperfusion, by Type USD Million (2025-2030)
  • Table 366. Argentina Hemoperfusion, by Application USD Million (2025-2030)
  • Table 367. Argentina Hemoperfusion, by Hemoperfusion Devices USD Million (2025-2030)
  • Table 368. Argentina Hemoperfusion, by Raw Material USD Million (2025-2030)
  • Table 369. Argentina Hemoperfusion, by Sorbent USD Million (2025-2030)
  • Table 370. Rest of South America Hemoperfusion, by Type USD Million (2025-2030)
  • Table 371. Rest of South America Hemoperfusion, by Application USD Million (2025-2030)
  • Table 372. Rest of South America Hemoperfusion, by Hemoperfusion Devices USD Million (2025-2030)
  • Table 373. Rest of South America Hemoperfusion, by Raw Material USD Million (2025-2030)
  • Table 374. Rest of South America Hemoperfusion, by Sorbent USD Million (2025-2030)
  • Table 375. Asia Pacific Hemoperfusion, by Country USD Million (2025-2030)
  • Table 376. Asia Pacific Hemoperfusion, by Type USD Million (2025-2030)
  • Table 377. Asia Pacific Hemoperfusion, by Application USD Million (2025-2030)
  • Table 378. Asia Pacific Hemoperfusion, by Hemoperfusion Devices USD Million (2025-2030)
  • Table 379. Asia Pacific Hemoperfusion, by Raw Material USD Million (2025-2030)
  • Table 380. Asia Pacific Hemoperfusion, by Sorbent USD Million (2025-2030)
  • Table 381. China Hemoperfusion, by Type USD Million (2025-2030)
  • Table 382. China Hemoperfusion, by Application USD Million (2025-2030)
  • Table 383. China Hemoperfusion, by Hemoperfusion Devices USD Million (2025-2030)
  • Table 384. China Hemoperfusion, by Raw Material USD Million (2025-2030)
  • Table 385. China Hemoperfusion, by Sorbent USD Million (2025-2030)
  • Table 386. Japan Hemoperfusion, by Type USD Million (2025-2030)
  • Table 387. Japan Hemoperfusion, by Application USD Million (2025-2030)
  • Table 388. Japan Hemoperfusion, by Hemoperfusion Devices USD Million (2025-2030)
  • Table 389. Japan Hemoperfusion, by Raw Material USD Million (2025-2030)
  • Table 390. Japan Hemoperfusion, by Sorbent USD Million (2025-2030)
  • Table 391. India Hemoperfusion, by Type USD Million (2025-2030)
  • Table 392. India Hemoperfusion, by Application USD Million (2025-2030)
  • Table 393. India Hemoperfusion, by Hemoperfusion Devices USD Million (2025-2030)
  • Table 394. India Hemoperfusion, by Raw Material USD Million (2025-2030)
  • Table 395. India Hemoperfusion, by Sorbent USD Million (2025-2030)
  • Table 396. South Korea Hemoperfusion, by Type USD Million (2025-2030)
  • Table 397. South Korea Hemoperfusion, by Application USD Million (2025-2030)
  • Table 398. South Korea Hemoperfusion, by Hemoperfusion Devices USD Million (2025-2030)
  • Table 399. South Korea Hemoperfusion, by Raw Material USD Million (2025-2030)
  • Table 400. South Korea Hemoperfusion, by Sorbent USD Million (2025-2030)
  • Table 401. Taiwan Hemoperfusion, by Type USD Million (2025-2030)
  • Table 402. Taiwan Hemoperfusion, by Application USD Million (2025-2030)
  • Table 403. Taiwan Hemoperfusion, by Hemoperfusion Devices USD Million (2025-2030)
  • Table 404. Taiwan Hemoperfusion, by Raw Material USD Million (2025-2030)
  • Table 405. Taiwan Hemoperfusion, by Sorbent USD Million (2025-2030)
  • Table 406. Australia Hemoperfusion, by Type USD Million (2025-2030)
  • Table 407. Australia Hemoperfusion, by Application USD Million (2025-2030)
  • Table 408. Australia Hemoperfusion, by Hemoperfusion Devices USD Million (2025-2030)
  • Table 409. Australia Hemoperfusion, by Raw Material USD Million (2025-2030)
  • Table 410. Australia Hemoperfusion, by Sorbent USD Million (2025-2030)
  • Table 411. Rest of Asia-Pacific Hemoperfusion, by Type USD Million (2025-2030)
  • Table 412. Rest of Asia-Pacific Hemoperfusion, by Application USD Million (2025-2030)
  • Table 413. Rest of Asia-Pacific Hemoperfusion, by Hemoperfusion Devices USD Million (2025-2030)
  • Table 414. Rest of Asia-Pacific Hemoperfusion, by Raw Material USD Million (2025-2030)
  • Table 415. Rest of Asia-Pacific Hemoperfusion, by Sorbent USD Million (2025-2030)
  • Table 416. Europe Hemoperfusion, by Country USD Million (2025-2030)
  • Table 417. Europe Hemoperfusion, by Type USD Million (2025-2030)
  • Table 418. Europe Hemoperfusion, by Application USD Million (2025-2030)
  • Table 419. Europe Hemoperfusion, by Hemoperfusion Devices USD Million (2025-2030)
  • Table 420. Europe Hemoperfusion, by Raw Material USD Million (2025-2030)
  • Table 421. Europe Hemoperfusion, by Sorbent USD Million (2025-2030)
  • Table 422. Germany Hemoperfusion, by Type USD Million (2025-2030)
  • Table 423. Germany Hemoperfusion, by Application USD Million (2025-2030)
  • Table 424. Germany Hemoperfusion, by Hemoperfusion Devices USD Million (2025-2030)
  • Table 425. Germany Hemoperfusion, by Raw Material USD Million (2025-2030)
  • Table 426. Germany Hemoperfusion, by Sorbent USD Million (2025-2030)
  • Table 427. France Hemoperfusion, by Type USD Million (2025-2030)
  • Table 428. France Hemoperfusion, by Application USD Million (2025-2030)
  • Table 429. France Hemoperfusion, by Hemoperfusion Devices USD Million (2025-2030)
  • Table 430. France Hemoperfusion, by Raw Material USD Million (2025-2030)
  • Table 431. France Hemoperfusion, by Sorbent USD Million (2025-2030)
  • Table 432. Italy Hemoperfusion, by Type USD Million (2025-2030)
  • Table 433. Italy Hemoperfusion, by Application USD Million (2025-2030)
  • Table 434. Italy Hemoperfusion, by Hemoperfusion Devices USD Million (2025-2030)
  • Table 435. Italy Hemoperfusion, by Raw Material USD Million (2025-2030)
  • Table 436. Italy Hemoperfusion, by Sorbent USD Million (2025-2030)
  • Table 437. United Kingdom Hemoperfusion, by Type USD Million (2025-2030)
  • Table 438. United Kingdom Hemoperfusion, by Application USD Million (2025-2030)
  • Table 439. United Kingdom Hemoperfusion, by Hemoperfusion Devices USD Million (2025-2030)
  • Table 440. United Kingdom Hemoperfusion, by Raw Material USD Million (2025-2030)
  • Table 441. United Kingdom Hemoperfusion, by Sorbent USD Million (2025-2030)
  • Table 442. Netherlands Hemoperfusion, by Type USD Million (2025-2030)
  • Table 443. Netherlands Hemoperfusion, by Application USD Million (2025-2030)
  • Table 444. Netherlands Hemoperfusion, by Hemoperfusion Devices USD Million (2025-2030)
  • Table 445. Netherlands Hemoperfusion, by Raw Material USD Million (2025-2030)
  • Table 446. Netherlands Hemoperfusion, by Sorbent USD Million (2025-2030)
  • Table 447. Rest of Europe Hemoperfusion, by Type USD Million (2025-2030)
  • Table 448. Rest of Europe Hemoperfusion, by Application USD Million (2025-2030)
  • Table 449. Rest of Europe Hemoperfusion, by Hemoperfusion Devices USD Million (2025-2030)
  • Table 450. Rest of Europe Hemoperfusion, by Raw Material USD Million (2025-2030)
  • Table 451. Rest of Europe Hemoperfusion, by Sorbent USD Million (2025-2030)
  • Table 452. MEA Hemoperfusion, by Country USD Million (2025-2030)
  • Table 453. MEA Hemoperfusion, by Type USD Million (2025-2030)
  • Table 454. MEA Hemoperfusion, by Application USD Million (2025-2030)
  • Table 455. MEA Hemoperfusion, by Hemoperfusion Devices USD Million (2025-2030)
  • Table 456. MEA Hemoperfusion, by Raw Material USD Million (2025-2030)
  • Table 457. MEA Hemoperfusion, by Sorbent USD Million (2025-2030)
  • Table 458. Middle East Hemoperfusion, by Type USD Million (2025-2030)
  • Table 459. Middle East Hemoperfusion, by Application USD Million (2025-2030)
  • Table 460. Middle East Hemoperfusion, by Hemoperfusion Devices USD Million (2025-2030)
  • Table 461. Middle East Hemoperfusion, by Raw Material USD Million (2025-2030)
  • Table 462. Middle East Hemoperfusion, by Sorbent USD Million (2025-2030)
  • Table 463. Africa Hemoperfusion, by Type USD Million (2025-2030)
  • Table 464. Africa Hemoperfusion, by Application USD Million (2025-2030)
  • Table 465. Africa Hemoperfusion, by Hemoperfusion Devices USD Million (2025-2030)
  • Table 466. Africa Hemoperfusion, by Raw Material USD Million (2025-2030)
  • Table 467. Africa Hemoperfusion, by Sorbent USD Million (2025-2030)
  • Table 468. North America Hemoperfusion, by Country USD Million (2025-2030)
  • Table 469. North America Hemoperfusion, by Type USD Million (2025-2030)
  • Table 470. North America Hemoperfusion, by Application USD Million (2025-2030)
  • Table 471. North America Hemoperfusion, by Hemoperfusion Devices USD Million (2025-2030)
  • Table 472. North America Hemoperfusion, by Raw Material USD Million (2025-2030)
  • Table 473. North America Hemoperfusion, by Sorbent USD Million (2025-2030)
  • Table 474. United States Hemoperfusion, by Type USD Million (2025-2030)
  • Table 475. United States Hemoperfusion, by Application USD Million (2025-2030)
  • Table 476. United States Hemoperfusion, by Hemoperfusion Devices USD Million (2025-2030)
  • Table 477. United States Hemoperfusion, by Raw Material USD Million (2025-2030)
  • Table 478. United States Hemoperfusion, by Sorbent USD Million (2025-2030)
  • Table 479. Canada Hemoperfusion, by Type USD Million (2025-2030)
  • Table 480. Canada Hemoperfusion, by Application USD Million (2025-2030)
  • Table 481. Canada Hemoperfusion, by Hemoperfusion Devices USD Million (2025-2030)
  • Table 482. Canada Hemoperfusion, by Raw Material USD Million (2025-2030)
  • Table 483. Canada Hemoperfusion, by Sorbent USD Million (2025-2030)
  • Table 484. Mexico Hemoperfusion, by Type USD Million (2025-2030)
  • Table 485. Mexico Hemoperfusion, by Application USD Million (2025-2030)
  • Table 486. Mexico Hemoperfusion, by Hemoperfusion Devices USD Million (2025-2030)
  • Table 487. Mexico Hemoperfusion, by Raw Material USD Million (2025-2030)
  • Table 488. Mexico Hemoperfusion, by Sorbent USD Million (2025-2030)
  • Table 489. Hemoperfusion Sales: by Type(K Units)
  • Table 490. Hemoperfusion Sales Charcoal Hemoperfusion , by Region K Units (2025-2030)
  • Table 491. Hemoperfusion Sales Certain Resins Hemoperfusion , by Region K Units (2025-2030)
  • Table 492. Hemoperfusion Sales: by Application(K Units)
  • Table 493. Hemoperfusion Sales Drug Intoxication , by Region K Units (2025-2030)
  • Table 494. Hemoperfusion Sales Hepatic Encephalopathy , by Region K Units (2025-2030)
  • Table 495. Hemoperfusion Sales Others , by Region K Units (2025-2030)
  • Table 496. Hemoperfusion Sales: by Hemoperfusion Devices(K Units)
  • Table 497. Hemoperfusion Sales DiaKart , by Region K Units (2025-2030)
  • Table 498. Hemoperfusion Sales Biocompatible System , by Region K Units (2025-2030)
  • Table 499. Hemoperfusion Sales Hemokart or Alukart , by Region K Units (2025-2030)
  • Table 500. Hemoperfusion Sales Adsorba , by Region K Units (2025-2030)
  • Table 501. Hemoperfusion Sales Hemopur , by Region K Units (2025-2030)
  • Table 502. Hemoperfusion Sales Others , by Region K Units (2025-2030)
  • Table 503. Hemoperfusion Sales: by Raw Material(K Units)
  • Table 504. Hemoperfusion Sales Polypropylene , by Region K Units (2025-2030)
  • Table 505. Hemoperfusion Sales Polycarbonate , by Region K Units (2025-2030)
  • Table 506. Hemoperfusion Sales Membrane Materials , by Region K Units (2025-2030)
  • Table 507. Hemoperfusion Sales Activated Carbon , by Region K Units (2025-2030)
  • Table 508. Hemoperfusion Sales: by Sorbent(K Units)
  • Table 509. Hemoperfusion Sales Petroleum Based Charcoal , by Region K Units (2025-2030)
  • Table 510. Hemoperfusion Sales Norit , by Region K Units (2025-2030)
  • Table 511. Hemoperfusion Sales Norit Extruded Charcoal , by Region K Units (2025-2030)
  • Table 512. Hemoperfusion Sales Others , by Region K Units (2025-2030)
  • Table 513. South America Hemoperfusion Sales, by Country K Units (2025-2030)
  • Table 514. South America Hemoperfusion Sales, by Type K Units (2025-2030)
  • Table 515. South America Hemoperfusion Sales, by Application K Units (2025-2030)
  • Table 516. South America Hemoperfusion Sales, by Hemoperfusion Devices K Units (2025-2030)
  • Table 517. South America Hemoperfusion Sales, by Raw Material K Units (2025-2030)
  • Table 518. South America Hemoperfusion Sales, by Sorbent K Units (2025-2030)
  • Table 519. Brazil Hemoperfusion Sales, by Type K Units (2025-2030)
  • Table 520. Brazil Hemoperfusion Sales, by Application K Units (2025-2030)
  • Table 521. Brazil Hemoperfusion Sales, by Hemoperfusion Devices K Units (2025-2030)
  • Table 522. Brazil Hemoperfusion Sales, by Raw Material K Units (2025-2030)
  • Table 523. Brazil Hemoperfusion Sales, by Sorbent K Units (2025-2030)
  • Table 524. Argentina Hemoperfusion Sales, by Type K Units (2025-2030)
  • Table 525. Argentina Hemoperfusion Sales, by Application K Units (2025-2030)
  • Table 526. Argentina Hemoperfusion Sales, by Hemoperfusion Devices K Units (2025-2030)
  • Table 527. Argentina Hemoperfusion Sales, by Raw Material K Units (2025-2030)
  • Table 528. Argentina Hemoperfusion Sales, by Sorbent K Units (2025-2030)
  • Table 529. Rest of South America Hemoperfusion Sales, by Type K Units (2025-2030)
  • Table 530. Rest of South America Hemoperfusion Sales, by Application K Units (2025-2030)
  • Table 531. Rest of South America Hemoperfusion Sales, by Hemoperfusion Devices K Units (2025-2030)
  • Table 532. Rest of South America Hemoperfusion Sales, by Raw Material K Units (2025-2030)
  • Table 533. Rest of South America Hemoperfusion Sales, by Sorbent K Units (2025-2030)
  • Table 534. Asia Pacific Hemoperfusion Sales, by Country K Units (2025-2030)
  • Table 535. Asia Pacific Hemoperfusion Sales, by Type K Units (2025-2030)
  • Table 536. Asia Pacific Hemoperfusion Sales, by Application K Units (2025-2030)
  • Table 537. Asia Pacific Hemoperfusion Sales, by Hemoperfusion Devices K Units (2025-2030)
  • Table 538. Asia Pacific Hemoperfusion Sales, by Raw Material K Units (2025-2030)
  • Table 539. Asia Pacific Hemoperfusion Sales, by Sorbent K Units (2025-2030)
  • Table 540. China Hemoperfusion Sales, by Type K Units (2025-2030)
  • Table 541. China Hemoperfusion Sales, by Application K Units (2025-2030)
  • Table 542. China Hemoperfusion Sales, by Hemoperfusion Devices K Units (2025-2030)
  • Table 543. China Hemoperfusion Sales, by Raw Material K Units (2025-2030)
  • Table 544. China Hemoperfusion Sales, by Sorbent K Units (2025-2030)
  • Table 545. Japan Hemoperfusion Sales, by Type K Units (2025-2030)
  • Table 546. Japan Hemoperfusion Sales, by Application K Units (2025-2030)
  • Table 547. Japan Hemoperfusion Sales, by Hemoperfusion Devices K Units (2025-2030)
  • Table 548. Japan Hemoperfusion Sales, by Raw Material K Units (2025-2030)
  • Table 549. Japan Hemoperfusion Sales, by Sorbent K Units (2025-2030)
  • Table 550. India Hemoperfusion Sales, by Type K Units (2025-2030)
  • Table 551. India Hemoperfusion Sales, by Application K Units (2025-2030)
  • Table 552. India Hemoperfusion Sales, by Hemoperfusion Devices K Units (2025-2030)
  • Table 553. India Hemoperfusion Sales, by Raw Material K Units (2025-2030)
  • Table 554. India Hemoperfusion Sales, by Sorbent K Units (2025-2030)
  • Table 555. South Korea Hemoperfusion Sales, by Type K Units (2025-2030)
  • Table 556. South Korea Hemoperfusion Sales, by Application K Units (2025-2030)
  • Table 557. South Korea Hemoperfusion Sales, by Hemoperfusion Devices K Units (2025-2030)
  • Table 558. South Korea Hemoperfusion Sales, by Raw Material K Units (2025-2030)
  • Table 559. South Korea Hemoperfusion Sales, by Sorbent K Units (2025-2030)
  • Table 560. Taiwan Hemoperfusion Sales, by Type K Units (2025-2030)
  • Table 561. Taiwan Hemoperfusion Sales, by Application K Units (2025-2030)
  • Table 562. Taiwan Hemoperfusion Sales, by Hemoperfusion Devices K Units (2025-2030)
  • Table 563. Taiwan Hemoperfusion Sales, by Raw Material K Units (2025-2030)
  • Table 564. Taiwan Hemoperfusion Sales, by Sorbent K Units (2025-2030)
  • Table 565. Australia Hemoperfusion Sales, by Type K Units (2025-2030)
  • Table 566. Australia Hemoperfusion Sales, by Application K Units (2025-2030)
  • Table 567. Australia Hemoperfusion Sales, by Hemoperfusion Devices K Units (2025-2030)
  • Table 568. Australia Hemoperfusion Sales, by Raw Material K Units (2025-2030)
  • Table 569. Australia Hemoperfusion Sales, by Sorbent K Units (2025-2030)
  • Table 570. Rest of Asia-Pacific Hemoperfusion Sales, by Type K Units (2025-2030)
  • Table 571. Rest of Asia-Pacific Hemoperfusion Sales, by Application K Units (2025-2030)
  • Table 572. Rest of Asia-Pacific Hemoperfusion Sales, by Hemoperfusion Devices K Units (2025-2030)
  • Table 573. Rest of Asia-Pacific Hemoperfusion Sales, by Raw Material K Units (2025-2030)
  • Table 574. Rest of Asia-Pacific Hemoperfusion Sales, by Sorbent K Units (2025-2030)
  • Table 575. Europe Hemoperfusion Sales, by Country K Units (2025-2030)
  • Table 576. Europe Hemoperfusion Sales, by Type K Units (2025-2030)
  • Table 577. Europe Hemoperfusion Sales, by Application K Units (2025-2030)
  • Table 578. Europe Hemoperfusion Sales, by Hemoperfusion Devices K Units (2025-2030)
  • Table 579. Europe Hemoperfusion Sales, by Raw Material K Units (2025-2030)
  • Table 580. Europe Hemoperfusion Sales, by Sorbent K Units (2025-2030)
  • Table 581. Germany Hemoperfusion Sales, by Type K Units (2025-2030)
  • Table 582. Germany Hemoperfusion Sales, by Application K Units (2025-2030)
  • Table 583. Germany Hemoperfusion Sales, by Hemoperfusion Devices K Units (2025-2030)
  • Table 584. Germany Hemoperfusion Sales, by Raw Material K Units (2025-2030)
  • Table 585. Germany Hemoperfusion Sales, by Sorbent K Units (2025-2030)
  • Table 586. France Hemoperfusion Sales, by Type K Units (2025-2030)
  • Table 587. France Hemoperfusion Sales, by Application K Units (2025-2030)
  • Table 588. France Hemoperfusion Sales, by Hemoperfusion Devices K Units (2025-2030)
  • Table 589. France Hemoperfusion Sales, by Raw Material K Units (2025-2030)
  • Table 590. France Hemoperfusion Sales, by Sorbent K Units (2025-2030)
  • Table 591. Italy Hemoperfusion Sales, by Type K Units (2025-2030)
  • Table 592. Italy Hemoperfusion Sales, by Application K Units (2025-2030)
  • Table 593. Italy Hemoperfusion Sales, by Hemoperfusion Devices K Units (2025-2030)
  • Table 594. Italy Hemoperfusion Sales, by Raw Material K Units (2025-2030)
  • Table 595. Italy Hemoperfusion Sales, by Sorbent K Units (2025-2030)
  • Table 596. United Kingdom Hemoperfusion Sales, by Type K Units (2025-2030)
  • Table 597. United Kingdom Hemoperfusion Sales, by Application K Units (2025-2030)
  • Table 598. United Kingdom Hemoperfusion Sales, by Hemoperfusion Devices K Units (2025-2030)
  • Table 599. United Kingdom Hemoperfusion Sales, by Raw Material K Units (2025-2030)
  • Table 600. United Kingdom Hemoperfusion Sales, by Sorbent K Units (2025-2030)
  • Table 601. Netherlands Hemoperfusion Sales, by Type K Units (2025-2030)
  • Table 602. Netherlands Hemoperfusion Sales, by Application K Units (2025-2030)
  • Table 603. Netherlands Hemoperfusion Sales, by Hemoperfusion Devices K Units (2025-2030)
  • Table 604. Netherlands Hemoperfusion Sales, by Raw Material K Units (2025-2030)
  • Table 605. Netherlands Hemoperfusion Sales, by Sorbent K Units (2025-2030)
  • Table 606. Rest of Europe Hemoperfusion Sales, by Type K Units (2025-2030)
  • Table 607. Rest of Europe Hemoperfusion Sales, by Application K Units (2025-2030)
  • Table 608. Rest of Europe Hemoperfusion Sales, by Hemoperfusion Devices K Units (2025-2030)
  • Table 609. Rest of Europe Hemoperfusion Sales, by Raw Material K Units (2025-2030)
  • Table 610. Rest of Europe Hemoperfusion Sales, by Sorbent K Units (2025-2030)
  • Table 611. MEA Hemoperfusion Sales, by Country K Units (2025-2030)
  • Table 612. MEA Hemoperfusion Sales, by Type K Units (2025-2030)
  • Table 613. MEA Hemoperfusion Sales, by Application K Units (2025-2030)
  • Table 614. MEA Hemoperfusion Sales, by Hemoperfusion Devices K Units (2025-2030)
  • Table 615. MEA Hemoperfusion Sales, by Raw Material K Units (2025-2030)
  • Table 616. MEA Hemoperfusion Sales, by Sorbent K Units (2025-2030)
  • Table 617. Middle East Hemoperfusion Sales, by Type K Units (2025-2030)
  • Table 618. Middle East Hemoperfusion Sales, by Application K Units (2025-2030)
  • Table 619. Middle East Hemoperfusion Sales, by Hemoperfusion Devices K Units (2025-2030)
  • Table 620. Middle East Hemoperfusion Sales, by Raw Material K Units (2025-2030)
  • Table 621. Middle East Hemoperfusion Sales, by Sorbent K Units (2025-2030)
  • Table 622. Africa Hemoperfusion Sales, by Type K Units (2025-2030)
  • Table 623. Africa Hemoperfusion Sales, by Application K Units (2025-2030)
  • Table 624. Africa Hemoperfusion Sales, by Hemoperfusion Devices K Units (2025-2030)
  • Table 625. Africa Hemoperfusion Sales, by Raw Material K Units (2025-2030)
  • Table 626. Africa Hemoperfusion Sales, by Sorbent K Units (2025-2030)
  • Table 627. North America Hemoperfusion Sales, by Country K Units (2025-2030)
  • Table 628. North America Hemoperfusion Sales, by Type K Units (2025-2030)
  • Table 629. North America Hemoperfusion Sales, by Application K Units (2025-2030)
  • Table 630. North America Hemoperfusion Sales, by Hemoperfusion Devices K Units (2025-2030)
  • Table 631. North America Hemoperfusion Sales, by Raw Material K Units (2025-2030)
  • Table 632. North America Hemoperfusion Sales, by Sorbent K Units (2025-2030)
  • Table 633. United States Hemoperfusion Sales, by Type K Units (2025-2030)
  • Table 634. United States Hemoperfusion Sales, by Application K Units (2025-2030)
  • Table 635. United States Hemoperfusion Sales, by Hemoperfusion Devices K Units (2025-2030)
  • Table 636. United States Hemoperfusion Sales, by Raw Material K Units (2025-2030)
  • Table 637. United States Hemoperfusion Sales, by Sorbent K Units (2025-2030)
  • Table 638. Canada Hemoperfusion Sales, by Type K Units (2025-2030)
  • Table 639. Canada Hemoperfusion Sales, by Application K Units (2025-2030)
  • Table 640. Canada Hemoperfusion Sales, by Hemoperfusion Devices K Units (2025-2030)
  • Table 641. Canada Hemoperfusion Sales, by Raw Material K Units (2025-2030)
  • Table 642. Canada Hemoperfusion Sales, by Sorbent K Units (2025-2030)
  • Table 643. Mexico Hemoperfusion Sales, by Type K Units (2025-2030)
  • Table 644. Mexico Hemoperfusion Sales, by Application K Units (2025-2030)
  • Table 645. Mexico Hemoperfusion Sales, by Hemoperfusion Devices K Units (2025-2030)
  • Table 646. Mexico Hemoperfusion Sales, by Raw Material K Units (2025-2030)
  • Table 647. Mexico Hemoperfusion Sales, by Sorbent K Units (2025-2030)
  • Table 648. Hemoperfusion: by Type(USD/Units)
  • Table 649. Research Programs/Design for This Report
  • Table 650. Key Data Information from Secondary Sources
  • Table 651. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Hemoperfusion: by Type USD Million (2018-2023)
  • Figure 5. Global Hemoperfusion: by Application USD Million (2018-2023)
  • Figure 6. Global Hemoperfusion: by Hemoperfusion Devices USD Million (2018-2023)
  • Figure 7. Global Hemoperfusion: by Raw Material USD Million (2018-2023)
  • Figure 8. Global Hemoperfusion: by Sorbent USD Million (2018-2023)
  • Figure 9. South America Hemoperfusion Share (%), by Country
  • Figure 10. Asia Pacific Hemoperfusion Share (%), by Country
  • Figure 11. Europe Hemoperfusion Share (%), by Country
  • Figure 12. MEA Hemoperfusion Share (%), by Country
  • Figure 13. North America Hemoperfusion Share (%), by Country
  • Figure 14. Global Hemoperfusion: by Type K Units (2018-2023)
  • Figure 15. Global Hemoperfusion: by Application K Units (2018-2023)
  • Figure 16. Global Hemoperfusion: by Hemoperfusion Devices K Units (2018-2023)
  • Figure 17. Global Hemoperfusion: by Raw Material K Units (2018-2023)
  • Figure 18. Global Hemoperfusion: by Sorbent K Units (2018-2023)
  • Figure 19. South America Hemoperfusion Share (%), by Country
  • Figure 20. Asia Pacific Hemoperfusion Share (%), by Country
  • Figure 21. Europe Hemoperfusion Share (%), by Country
  • Figure 22. MEA Hemoperfusion Share (%), by Country
  • Figure 23. North America Hemoperfusion Share (%), by Country
  • Figure 24. Global Hemoperfusion: by Type USD/Units (2018-2023)
  • Figure 25. Global Hemoperfusion share by Players 2023 (%)
  • Figure 26. Global Hemoperfusion share by Players (Top 3) 2023(%)
  • Figure 27. Global Hemoperfusion share by Players (Top 5) 2023(%)
  • Figure 28. BCG Matrix for key Companies
  • Figure 29. Gambro (United States) Revenue, Net Income and Gross profit
  • Figure 30. Gambro (United States) Revenue: by Geography 2023
  • Figure 31. Organon-Teknika (United States) Revenue, Net Income and Gross profit
  • Figure 32. Organon-Teknika (United States) Revenue: by Geography 2023
  • Figure 33. Smith and Nephew (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 34. Smith and Nephew (United Kingdom) Revenue: by Geography 2023
  • Figure 35. Cytosorbents (United States) Revenue, Net Income and Gross profit
  • Figure 36. Cytosorbents (United States) Revenue: by Geography 2023
  • Figure 37. Asahi-Kasei (Japan) Revenue, Net Income and Gross profit
  • Figure 38. Asahi-Kasei (Japan) Revenue: by Geography 2023
  • Figure 39. Biosun Medical (China) Revenue, Net Income and Gross profit
  • Figure 40. Biosun Medical (China) Revenue: by Geography 2023
  • Figure 41. Toray Medical (Japan) Revenue, Net Income and Gross profit
  • Figure 42. Toray Medical (Japan) Revenue: by Geography 2023
  • Figure 43. Jafron Biomedical (China) Revenue, Net Income and Gross profit
  • Figure 44. Jafron Biomedical (China) Revenue: by Geography 2023
  • Figure 45. Baxter International (United States) Revenue, Net Income and Gross profit
  • Figure 46. Baxter International (United States) Revenue: by Geography 2023
  • Figure 47. Kaneka Corporation (Japan) Revenue, Net Income and Gross profit
  • Figure 48. Kaneka Corporation (Japan) Revenue: by Geography 2023
  • Figure 49. Global Hemoperfusion: by Type USD Million (2025-2030)
  • Figure 50. Global Hemoperfusion: by Application USD Million (2025-2030)
  • Figure 51. Global Hemoperfusion: by Hemoperfusion Devices USD Million (2025-2030)
  • Figure 52. Global Hemoperfusion: by Raw Material USD Million (2025-2030)
  • Figure 53. Global Hemoperfusion: by Sorbent USD Million (2025-2030)
  • Figure 54. South America Hemoperfusion Share (%), by Country
  • Figure 55. Asia Pacific Hemoperfusion Share (%), by Country
  • Figure 56. Europe Hemoperfusion Share (%), by Country
  • Figure 57. MEA Hemoperfusion Share (%), by Country
  • Figure 58. North America Hemoperfusion Share (%), by Country
  • Figure 59. Global Hemoperfusion: by Type K Units (2025-2030)
  • Figure 60. Global Hemoperfusion: by Application K Units (2025-2030)
  • Figure 61. Global Hemoperfusion: by Hemoperfusion Devices K Units (2025-2030)
  • Figure 62. Global Hemoperfusion: by Raw Material K Units (2025-2030)
  • Figure 63. Global Hemoperfusion: by Sorbent K Units (2025-2030)
  • Figure 64. South America Hemoperfusion Share (%), by Country
  • Figure 65. Asia Pacific Hemoperfusion Share (%), by Country
  • Figure 66. Europe Hemoperfusion Share (%), by Country
  • Figure 67. MEA Hemoperfusion Share (%), by Country
  • Figure 68. North America Hemoperfusion Share (%), by Country
  • Figure 69. Global Hemoperfusion: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • Gambro (United States)
  • Organon-Teknika (United States)
  • Smith and Nephew (United Kingdom)
  • Cytosorbents (United States)
  • Asahi-Kasei (Japan)
  • Biosun Medical (China)
  • Toray Medical (Japan)
  • Jafron Biomedical (China)
  • Baxter International (United States)
  • Kaneka Corporation (Japan)
Additional players considered in the study are as follows:
Toray Medical Co. Ltd. (Japan) , Fresenius SE & Co. KGaA (Germany) , B. Braun Melsungen AG (Germany) , Abbott Laboratories (United States)
Select User Access Type

Key Highlights of Report


Mar 2024 227 Pages 75 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Hemoperfusion Quantitative research analysis
Global Hemoperfusion Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Gambro (United States), Organon-Teknika (United States), Smith and Nephew (United Kingdom), Cytosorbents (United States), Asahi-Kasei (Japan), Biosun Medical (China), Toray Medical (Japan), Jafron Biomedical (China), Baxter International (United States) and Kaneka Corporation (Japan) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Increased Use of Hemoperfusion in Healthcare Such As Providing Supportive Treatment Before and After Transplantation for Patients In Case Of Liver Failure and Others" is seen as one of major influencing trends for Hemoperfusion Market during projected period 2023-2030.
The Hemoperfusion market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Hemoperfusion Report?

Have a Query? Click Here

Other Related Reports

Etanercept Comprehensive Study by Type (Enbrel, Benepali), Application (Rheumatoid arthritis, Psoriatic arthritis, Ankylosing spondylitis, Juvenile idiopathic arthritis (JIA), Others), Form Type (Inj...
$ 3650
Radiotherapy Comprehensive Study by Type (External Beam Radiotherapy (IMRT, IGRT, Others), Internal Beam Radiotherapy (LDR, HDR, PDR), Systemic Radiotherapy), Application (Prostate Cancer, Breast Can...
$ 3750
Autism Spectrum Disorder Comprehensive Study by Type (Applied Behavior Analysis, Discrete Trial Teaching, Pivotal Response Treatment), Indication (Insomnia, Epilepsy, Depression, Hyperactivity & Inat...
$ 3450
Blood Serum Comprehensive Study by Type (Bovine (Fetal Bovine, Newborn Calf, Calf, Adult Bovine), Equine, Porcine, Other), Application (Cell Culture Media, Cell Line Saving, Tissue Culture, Diagnosti...
$ 3500
Pigmented Lesion Treatment Comprehensive Study by Type (Energy Based Devices, RF Devices, Ultrasound Devices, IPL Devices), Application (Dermatology Clinics, Beauty Clinics, Hospitals), Treatment (La...
$ 3650
Stretch Marks Treatment Comprehensive Study by Type (Topical Products (Oils, Creams, and Lotion), Lasers (Pulse-Dye Laser, Fractional Laser, and Others), Microdermabrasion, Others), Application (Hosp...
$ 3450